Study shows large-scale genomic testing feasible, impacts therapy

November 15, 2012

Targeted cancer therapy has been transforming the care of patients with non-small-cell lung cancer (NSCLC). It is now standard practice for tumor specimens from NSCLC patients to be examined for EGFR mutations and ALK rearrangements to identify patients for therapy with EGFR and ALK inhibitors, respectively. Now, researchers say large-scale genomic testing is feasible within the clinical workflow, impacting therapeutic decisions. The study is published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology.

Researchers from the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in conjunction with the Center for Advanced Molecular Diagnostics in the Pathology Department at the Brigham and Women's Hospital and the Laboratory for at the Partners Healthcare Center for Personalized , introduced prospective geno¬typing of advanced NSCLC for somatic alterations in BRAF, HER2, PIK3CA, and ALK in July 2009, in addition to rou¬tine mutational analysis of EGFR and KRAS, which had been ongoing since 2004. Three-hundred forty-four specimens taken from 419 patients were successfully genotyped with a median turnaround time of 31 days.

"The goals of the genomic characterization of our NSCLC patients are to help guide therapy and ultimately lead to improved outcomes for those patients with specific genomic changes," the authors say. "As the repertoire of muta¬tions for which targeted may be offered expands in lung cancer and other solid malignancies, strategies to enable rapid, accurate and comprehensive clinical genotyping will be essential to successfully integrate tumor molecular analy¬sis into the fast pace of clinical decision making and yield its greatest potential impact on patient management."

Explore further: ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium

Related Stories

Study examines drug resistance in ALK positive lung cancer

January 19, 2012

Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell ...

New research confirms need for lung cancer testing

February 2, 2012

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.